Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 9/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 9/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.52 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.52 |
| ▸ | HSD17B3 | P37058 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | CASP7 | P55210 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL960904 | 0.95 | HSD17B3 (0.56) | RAF1MAP2K1CYP2C9BRAFMAP2K2 | |
| SCHEMBL30615264 | 0.95 | HSD17B3 (0.56) | RAF1MAP2K1CYP2C9BRAFMAP2K2 | |
| SCHEMBL15901773 | 0.84 | ALDH1A2 (0.60) | RAF1MAP2K1CYP2C9BRAFMAP2K2 | |
| SCHEMBL30615224 | 0.83 | MAP2K1 (0.74) | RAF1MAP2K1CYP2C9BRAFMAP2K2 | |
| SCHEMBL26613689 | 0.83 | MAP2K1 (0.74) | RAF1MAP2K1CYP2C9BRAFMAP2K2 | |
| SCHEMBL26613857 | 0.83 | HSD17B3 (0.56) | RAF1MAP2K1CYP2C9BRAFMAP2K2 | |
| SCHEMBL961016 | 0.83 | HSD17B3 (0.56) | RAF1MAP2K1CYP2C9BRAFMAP2K2 | |
| SCHEMBL17409845 | 0.82 | HSD17B3 (0.53) | RAF1MAP2K1CYP2C9BRAFMAP2K2 | |
| SCHEMBL962958 | 0.82 | RAF1 (0.45) | RAF1MAP2K1CYP2C9BRAFMAP2K2 | |
| SCHEMBL960890 | 0.82 | RAF1 (0.45) | RAF1MAP2K1CYP2C9BRAFMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133174-B2 | Method for producing coumarin derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-15 | — | — | US | disclosed |
| US-20140213786-A1 | Method for Producing Coumarin Derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213786-A1 | Method for Producing Coumarin Derivative | CYP3A7, CYP2B6, CYP7A1 | BRAF 1936/4885RAF1 689/4885MAP2K1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.